Osteoarthritis in dogs: does glucosamine–chondroitin supplementation vs placebo improve objective gait measures? — POSSIBLE (the treatment made no difference to objective gait measures)

In dogs with osteoarthritis, does glucosamine–chondroitin supplementation vs placebo improve objective gait measures?

Shelf #513 · gate-verified and displayed under the developer's blinded-trial rule

POSSIBLE (the treatment made no difference to objective gait measures): The null suffix is scoped to objective gait — on that measure, two blinded placebo-controlled trials agree. In Kampa 2023, a prospective, block-randomized, double-blinded, placebo-controlled trial in 75 owned dogs with hip osteoarthritis, the change in peak vertical force in the glucosamine hydrochloride/chondroitin sulfate group was -0.05 ± 6.34 at week 4 (placebo 0.08 ± 1.90) and 1.08 ± 5.49 at week 6 (placebo -0.33 ± 3.65) — between placebo and the groups that did separate (PCSO-524, EAB-277 and carprofen, all significant at weeks 4 and 6) and not itself significant. In Moreau 2003, a double-blind study in 71 dogs randomly assigned to a glucosamine/chondroitin-containing nutraceutical, carprofen, meloxicam or placebo, ground reaction forces were significantly improved by carprofen and meloxicam but not by the nutraceutical. The one positive trial, McCarthy 2007, cannot answer this shelf's question: it was randomised and double-blind but used carprofen as a positive control with no placebo group, and its outcomes were subjective veterinarian scores (significant improvements in pain, weight-bearing and condition severity by day 70, P<0.001), not objective gait measures. Design class (a): randomisation and blinding are both established by carded records (Kampa 2023, block-randomized and double-blinded, placebo-controlled; Moreau 2003, randomly assigned, double-blind). The honest limits: Kampa tested hip osteoarthritis for 6 weeks with peak vertical force only, Moreau's supplement was a multi-ingredient nutraceutical rather than glucosamine/chondroitin alone, and no carded trial shows an objective gait benefit at any duration — longer treatment is untested on objective measures, not disproven. Drafted Nov 10, 2026 (VetMed build, topic #513); all figures from abstracts fetched and verified at drafting.

Kampa 2023: glucosamine/chondroitin did not significantly improve peak vertical force in 75 dogs with hip osteoarthritis — its change lay between placebo and the carprofen, PCSO-524 and EAB-277 groups that did separate from placebo

Prospective, block-randomized, double-blinded, placebo-controlled clinical trial (record's own wording)

Who: Dogs: 75 owned pet dogs with hip osteoarthritis, assigned randomly into five treatment groups: PCSO-524 (a marine-based fatty acid compound), glucosamine and chondroitin sulfate (the record names the preparation generically as glucosamine hydrochloride and chondroitin sulfate; no brand or dose is stated in the abstract), EAB-277 (a marine-based fatty acid compound), carprofen, and placebo (sunflower oil). Peak vertical force (PVF) and subjective orthopedic assessment scores (OAS) were evaluated at week 0 and at weeks 2, 4 and 6. The abstract does not state the number of dogs per group.

Result: At week 2, only the carprofen group showed a significant increase in PVF (3.14 ± 5.33, mean ± SD). After 4 weeks, the increases in PVF in the PCSO-524 (3.90 ± 3.52), EAB-277 (4.17 ± 4.94) and carprofen (3.08 ± 5.87) groups were significant and significantly greater than placebo (0.08 ± 1.90) and glucosamine (-0.05 ± 6.34) groups. After 6 weeks, the change in PVF in the PCSO-524 (4.14 ± 4.65), EAB-277 (4.45 ± 4.23) and carprofen (4.21 ± 6.52) groups was significant and significantly higher than placebo (-0.33 ± 3.65); the change in the glucosamine group (1.08 ± 5.49) lay between the placebo group and the other treatment groups. The OAS did not show any significant change in any group. The authors conclude that PCSO-524 and EAB-277, but not glucosamine/chondroitin, resulted in significant improvements in PVF.

Watch out: This record carries no MeSH terms in PubMed (see source line), and a corrigendum to the article was published in the same journal in 2023 (PMID: 37601749, a published erratum notice; the figures carded here are from the original record's abstract). Six weeks in hip osteoarthritis only, one objective variable (PVF) — the trial does not test longer supplementation or other joints.

Kampa N, Kaenkangploo D, Jitpean S, Srithunyarat T, Seesupa S, Hoisang S, Yongvanit K, Kamlangchai P, Tuchpramuk P, Lascelles BDX. Study of the effectiveness of glucosamine and chondroitin sulfate, marine based fatty acid compounds (PCSO-524 and EAB-277), and carprofen for the treatment of dogs with hip osteoarthritis: A prospective, block-randomized, double-blinded, placebo-controlled clinical trial. Front Vet Sci. 2023;10:1033188. PMID: 36816197. Registry ID: none in the record. MeSH: none in the record (no MeSH terms are listed for this record)

Moreau 2003: ground reaction forces were significantly improved by carprofen and meloxicam but not by a glucosamine/chondroitin-containing nutraceutical in 71 dogs with osteoarthritis (the treatment made no difference to objective gait)

Prospective, double-blind randomised trial with placebo control (record's own wording: 'a prospective, double-blind study'; dogs 'randomly assigned' to treatments or placebo; publication type: Randomized Controlled Trial)

Who: Dogs: 71 client-owned dogs with osteoarthritis, randomly assigned to a nutraceutical, carprofen, meloxicam, or a placebo control group, with 10 normal dogs as a gait reference. The nutraceutical was a multi-ingredient preparation — its record's MeSH terms include glucosamine, chondroitin sulfates, ascorbic acid and manganese compounds — not glucosamine/chondroitin alone. Ground reaction forces of the arthritic limb, haematological and biochemical variables, and subjective assessments by owners and orthopaedic surgeons were measured before treatment and at 30 and 60 days.

Result: Changes in the ground reaction forces were specific to the arthritic joint, and were significantly improved by carprofen and meloxicam but not by the nutraceutical; the values returned to normal only with meloxicam. The orthopaedic surgeons assessed that there had been an improvement with carprofen and meloxicam, but the owners considered that there had been an improvement only with meloxicam. The treatments were well tolerated, except for a case of hepatopathy in a dog treated with carprofen.

Watch out: Because the supplement tested was a multi-ingredient nutraceutical, this card supports the shelf only as a glucosamine/chondroitin-containing preparation versus placebo on objective gait — it cannot isolate which ingredient did or did not act. The record's abstract gives no numerical ground-reaction-force values, so no effect size can be quoted from it; its role is the direction of the result alongside the trials that did detect NSAID effects in the same dogs.

Moreau M, Dupuis J, Bonneau NH, Desnoyers M. Clinical evaluation of a nutraceutical, carprofen and meloxicam for the treatment of dogs with osteoarthritis. Vet Rec. 2003;152(11):323-9. PMID: 12665145. Registry ID: none in the record. MeSH: Administration, Oral · Animals · Anti-Inflammatory Agents, Non-Steroidal/administration & dosage, therapeutic use* · Ascorbic Acid/administration & dosage, therapeutic use · Carbazoles/administration & dosage, therapeutic use · Chondroitin Sulfates/administration & dosage, therapeutic use · Chronic Disease · Dog Diseases/drug therapy*, pathology · Dogs · Double-Blind Method · Gait · Glucosamine/administration & dosage, therapeutic use · Lameness, Animal · Manganese Compounds/administration & dosage, therapeutic use · Meloxicam · Osteoarthritis/drug therapy, pathology, veterinary* · Osteoarthritis, Hip/drug therapy, pathology, veterinary · Osteoarthritis, Knee/drug therapy, pathology, veterinary · Prospective Studies · Severity of Illness Index · Stifle · Thiazines/administration & dosage, therapeutic use · Thiazoles/administration & dosage, therapeutic use · Treatment Outcome

McCarthy 2007: glucosamine/chondroitin improved subjective veterinarian scores by day 70 versus baseline in a carprofen-controlled trial — but with no placebo group and no objective gait measure it cannot answer the placebo/objective question

Randomised, double-blind, positive-controlled multi-centre trial (record's own wording: 'randomised, double-blind, positive controlled, multi-centre trial'; publication type: Randomized Controlled Trial) — no placebo group

Who: Dogs: 35 dogs with confirmed osteoarthritis of the hips or elbows in a multi-centre trial of an orally administered glucosamine hydrochloride and chondroitin sulfate combination, with carprofen as positive control (the record names the combination generically; no brand is stated in the abstract). Dogs were re-examined on days 14, 42 and 70 after initiation of treatment; medication was then withdrawn and dogs re-assessed on day 98. Response was based on subjective evaluation by participating veterinarians.

Result: Dogs treated with glucosamine/chondroitin showed statistically significant improvements in scores for pain, weight-bearing and severity of the condition by day 70 (P<0.001). Onset of significant response was slower for glucosamine/chondroitin than for carprofen-treated dogs. The authors conclude that glucosamine/chondroitin has a positive clinical effect in dogs with osteoarthritis.

Watch out: Positive-controlled means exactly that: there is no placebo arm, so improvement from baseline on subjective scores cannot be separated from placebo effects, regression to the mean, or natural fluctuation — effects documented in canine osteoarthritis trials. This card is on the shelf to explain why the widely quoted positive result does not contradict the two placebo-controlled objective-gait nulls above; it is not evidence of an objective gait benefit.

McCarthy G, O'Donovan J, Jones B, McAllister H, Seed M, Mooney C. Randomised double-blind, positive-controlled trial to assess the efficacy of glucosamine/chondroitin sulfate for the treatment of dogs with osteoarthritis. Vet J. 2007;174(1):54-61. PMID: 16647870. Registry ID: none in the record. MeSH: Administration, Oral · Animals · Anti-Inflammatory Agents, Non-Steroidal/therapeutic use · Carbazoles/therapeutic use · Chondroitin Sulfates/therapeutic use* · Dog Diseases/drug therapy*, pathology · Dogs · Double-Blind Method · Drug Therapy, Combination · Female · Glucosamine/therapeutic use* · Male · Osteoarthritis/drug therapy*, pathology, veterinary* · Prospective Studies · Statistics, Nonparametric

Synthesis: on objective gait measures, glucosamine–chondroitin has not separated from placebo in either blinded placebo-controlled trial that measured them, while NSAIDs in the same trials did; the positive literature result rests on subjective scores without a placebo group

Synthesis

Who: Synthesis of the cards above: Kampa 2023 (75 owned dogs with hip osteoarthritis, block-randomized double-blinded placebo-controlled, peak vertical force to 6 weeks), Moreau 2003 (71 dogs, double-blind, randomly assigned, nutraceutical vs carprofen vs meloxicam vs placebo, ground reaction forces to 60 days) and McCarthy 2007 (35 dogs, randomised double-blind, carprofen positive control, subjective veterinarian scores to day 70, no placebo).

Result: (1) Peak vertical force: glucosamine/chondroitin change was -0.05 ± 6.34 at week 4 and 1.08 ± 5.49 at week 6, against placebo 0.08 ± 1.90 and -0.33 ± 3.65, while carprofen and both marine fatty-acid compounds separated significantly from placebo (Kampa). (2) Ground reaction forces: significantly improved by carprofen and meloxicam but not by the glucosamine/chondroitin-containing nutraceutical (Moreau). (3) Subjective scores: significant improvement by day 70 in the one trial with no placebo group and no objective gait measure (McCarthy).

Watch out: The shelf answers the objective-gait question only. It does not claim glucosamine–chondroitin is harmful or that owners never perceive benefit, and it does not test treatment beyond 70 days, other specific commercial preparations (both carded supplement preparations are named only generically in their records), or joints other than those studied. Subjective improvement without a placebo control is a different, weaker claim than the one this shelf's question asks.

Synthesis of Kampa N et al. PMID: 36816197; Moreau M et al. PMID: 12665145; McCarthy G et al. PMID: 16647870. Registry IDs as on the individual cards.

Back to the library index · VetMed home

VetMed is an educational resource, not veterinary advice.